News and Press Releases
Press releases
Theralase® Provides Update on Phase II Bladder Cancer Study
Press ReleaseFor the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator (“PI”)) achieved a Complete Response (“CR”) at any assessment date post primary Study Treatment and 30% of Evaluable Patients ac...
Theralase Releases FY2022 Audited Financial Statements
Press ReleaseToronto, Ontario – April 26, 2023, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Ph...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
Press ReleaseToronto, Ontario – February 23, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated ...
Theralase® Awarded TSX Venture 50 ™ Recognition as a Top Performing Company
Press ReleaseToronto, Ontario – February 21, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting
Press ReleaseToronto, Ontario – February 2, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated ...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to Presented at the ASCO GU Cancer Symposium
Press ReleaseToronto, Ontario – January 25, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated ...
Theralase ® Announces Warrant Extension
Press ReleaseToronto, Ontario – January 5, 2023, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dyna...
Theralase Release’s Q322 Interim Financial Statements
Press ReleaseToronto, Ontario – November 29, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activat...
Theralase® Grants Stock Options
Press ReleaseToronto, Ontario – November 21, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated...
Theralase ® Closes Private Placement Equity Financing
Press ReleaseToronto, Ontario – November 17, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
